EFTR — Effector Therapeutics Share News
0.000.00%
HealthcareHighly SpeculativeMicro Cap
Brief: EFFECTOR Therapeutics Announces Positive Top-Line Results From Phase 1b Clinical Trial Of Zotatifin
U.S. RESEARCH ROUNDUP- Humana, JP Morgan, Voya Financial
Brief: Effector Therapeutics Provides Positive Clinical Data Update For Zotatifin And General Corporate Update
eFFECTOR Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: eFFECTOR Therapeutics Inc Reports Q3 Diluted Loss Per Share Of $0.23
eFFECTOR Therapeutics Inc expected to post a loss of 21 cents a share - Earnings Preview
Brief: Effector Therapeutics Completes Enrollment In Second Of Three Cohorts Of Phase 1B Clinical Trial Of Zotatifin For The Treatment Of Covid-19
U.S. STOCKS ON THE MOVE-Intel, Chip stocks, PepsiCo
Brief: eFFECTOR Therapeutics Appoints Mayank Gandhi, M.D., As Chief Business Officer
Brief: eFFECTOR Therapeutics Inc - Entered Into Controlled Equity Offering Sales Agreement With Cantor Fitzgerald & Co
Brief: eFFECTOR Therapeutics Inc Files For Mixed Shelf Of Up To $200 Million - SEC Filing
U.S. RESEARCH ROUNDUP- Axon Enterprise, Berkeley Lights, Minerva Surgical
Brief: Effector Therapeutics Q2 Loss Per Share $0.17
Brief: Effector Therapeutics Reports Positive Interim Results In Zotatifin Phase 1/2 Clinical Trial
Brief: Effector Therapeutics To Present Interim Data From Ongoing Zotatifin Phase 1/2 Dose Escalation And Expansion Trial
U.S. RESEARCH ROUNDUP- Appfolio, Hyatt Hotels, TransDigm Group
NASDAQ RESUMED AT 11:23 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:18 AM
U.S. RESEARCH ROUNDUP-Apellis Pharmaceuticals, ONEOK, Progressive